Pyxis Oncology appoints Michael A. Metzger (CEO of Syndax) to board effective June 10, 2024

Pyxis Oncology, Inc.

Michael A. Metzger appointed to Pyxis Oncology Board as Class II director, effective June 10, 2024.
Metzger is CEO of Syndax Pharmaceuticals (Nasdaq: SNDX) and has over 25 years biopharma experience.
He will serve on Audit and Compensation Committees; received stock options for 70,683 shares vesting over three years.
Board determined Metzger qualifies as independent director under Nasdaq standards.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael A. Metzger

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2024-06-10
Filed: June 10, 2024, 7:59 PM ET

On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael A. Metzger was appointed as Director at Pyxis Oncology, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).

View on SEC.gov

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-157911

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.